Cardiac Biomarkers Market
Cardiac Biomarkers Market Analysis By Product (Creatine Kinase, Troponins, Myoglobin, Natriuretic Peptides, Ischemia Modified Albumin (IMA)), By Application (Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure, Atherosclerosis), By Location of Testing (Point-of-care Testing, Laboratory Testing) & By Region – Global Market Insights 2023 to 2033
Analysis of Cardiac Biomarkers Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cardiac Biomarkers Market Outlook (2023 to 2033)
A newly published research report by Fact.MR says that the global cardiac biomarkers market stands at US$ 13.37 billion in 2023. Worldwide demand for cardiac biomarkers is projected to accelerate at a CAGR of 11% and reach a market value of US$ 38 billion by 2033.
Rising use of cardiac biomarkers as an integrated diagnostic approach against different cardiovascular diseases, including ischemia modified albumin (IMA), myoglobin, troponin I and T, brain natriuretic peptide (BNPs), myocardial muscle creatine kinase, and others is generating their higher demand.
Cardiac biomarkers are endogenous substances that include proteins, hormones, and enzymes that are released into the blood at the time of some specific cardiovascular conditions. These conditions indicate abnormalities in the functioning of the cardiac system. Healthcare providers are focusing on detecting these specific markers for the identification and diagnosis of critical cardiac conditions, including acute coronary syndrome (ACS), heart attack, etc.
- Worldwide demand for cardiac biomarkers for congestive heart failure is projected to increase at 12.3% CAGR through 2033.
- Siemens AG, F. Hoffmann-La Roche AG, and Abbott are three prominent companies operating globally. They account for around 30% share of the global market revenue.
In recent years, the burden of CVDs (cardiovascular diseases) has been increasing across the globe due to various factors, including diabetes, lifestyle changes, obesity, and smoking. Increasing cases related to heart diseases or disorders are predicted to fuel demand for effective tools for diagnosis, including cardiac biomarkers.
Robust R&D activities related to cardiovascular interventions along with the introduction of novel and more effective devices used for biomarker tests are projected to drive opportunities for players. They are investing to develop new biomarkers for diagnosis, prognosis, and predictive analysis of the disorders related to cardiovascular health.
For instance :
- In July 2019, Siemens received approval from the United States Food and Drug Administration for high-sensitivity troponin I assay. This aided in the diagnosis of myocardial infarction at early stages.
- In September 2019, Abbott received FDA approval for its blood test ARCHITECT STAT High Sensitivity Troponin-I. It is designed for the detection of heart attacks more accurately and quickly. These heart attack diagnostic tests are more effective than conventional tests.
These novel innovations are projected to lead to increased demand for more effective solutions and thus drive market opportunities. However, there are a few biomarkers that require comparatively more time to obtain results. In addition, sometimes these biomarkers also lead to multiple complications, including misdiagnosis.
Cardiac Biomarkers Market Size (2023)
US$ 13.37 Billion
Forecasted Market Value (2033)
US$ 38 Billion
Global Market Growth Rate (2023 to 2033)
Congestive Heart Failure Segment Growth Rate (2023 to 2033)
Extensively Used Cardiac Biomarkers
Revenue Share of Top 3 Companies (2022)
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is Demand for Cardiac Biomarkers Surging across the World?
“Rising Requirements of Cardiac Biomarkers to Speed Up Treatment Process”
Cardiac biomarkers are significantly used in the early diagnosis of numerous cardiovascular diseases, including heart attack, acute coronary syndrome, heart failure, and myocardial infarction. According to the WHO (World Health Organization), a lot of people around the world are encountering strokes or myocardial infarctions on an annual basis.
Acute coronary syndrome is a common complication faced by patients with coronary heart disease. Various patients need to undergo hospitalization due to the seriousness of the issue. Therefore, the growing incidences of cardiovascular diseases are projected to lead to the rising requirements for early diagnosis to get timely treatment, leading to the rising adoption of technologically advanced cardiac biomarker tests.
“Emerging Markets with Increasing Cases of Heart Issues”
Several emerging markets, including India, provide significant growth opportunities for suppliers of cardiac diagnostic solutions because of the rising population of heart patients. The rising burden of different types of cardiovascular diseases in these countries is due to multiple factors, including high blood pressure, diabetes, obesity, etc., thus creating opportunities for suppliers.
What’s Restraining the Sales Growth of Cardiac Biomarkers?
“Technical Issues Related to Collection and Storage of Samples”
Cardiac biomarkers are extensively used in epidemiology studies to complete the investigation of numerous stages of disorders in human beings. The process requires more careful handling as well as storage of numerous precious biological samples to get detailed information from limited samples.
Strong quality control measures are required for these samples to offer appropriate conditions of storage to avoid data loss. Studies through cardiac biomarkers use archived specimens and are dependent on the specimens’ integrity and manner of collection, process, and storage. Technical issues in sample collection as well as storage are projected to hamper expansion opportunities over the coming decade.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What are the Strategies Adopted by New Manufacturers to Increase their Market Presence?
“Increased R&D Investments for Development of Novel Cardiac Biomarkers”
Start-ups are spending at a significant rate to develop more efficient and novel cardiac biomarkers. Since conventional cardiac biomarkers lack specificity and require more sensitive cardiac biomarker study of the patients, a need arises for more appropriate solutions.
New entrants are spending on R&D activities to develop technologically advanced cardiac biomarkers. These biomarkers come with more advanced facilities to collect and store samples of patients and ensure authentic analysis of the same. Ambulatory surgical centers across developed countries are also projected to drive the business of specialty clinics, thus contributing to biomarker testing market expansion over the coming 10 years.
How is the United States Market Predicted to Perform Over the Forecast Period?
“Presence of Several Prominent Players and Strong Product Portfolio”
The United States is estimated to maintain its dominance across North America in the coming decade. The increasing expenditure on R&D activities related to healthcare facilities is leading to advancements in cardiac biomarkers. In addition, the presence of various prominent players and their strong product portfolios are generating lucrative market opportunities.
What is Propelling the Demand for Cardiac Biomarkers in China and India?
“Introduction of Multiple Technologically Advanced Cardiac Biomarkers”
Markets in China and India are expected to progress at a significant rate during the projected period because of the introduction of various technologically advanced cardiac biomarkers. Moreover, the developing healthcare infrastructure is also leading to increased opportunities for suppliers in India and China.
Which European Country is Considered Highly Profitable for Market Players?
“Growing Incidence of Myocardial Infarction and Acute Coronary Syndrome in the United Kingdom”
Rising cases of myocardial infarction and acute coronary syndrome are leading to the increasing demand for cardiac biomarkers in the United Kingdom and thus widening the horizon for industry players.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
What is Stimulating the Demand for Troponin across Geographies?
“Rising Cases of Acute Coronary Syndrome and Myocardial Infarction”
Based on product, the global market is classified into troponin, creatine kinase (CK), myoglobin, natriuretic peptides, and ischemia modified albumin (IMA). Among these, demand for troponins is predicted to significantly increase because of the growing preference among various end users.
Troponin tests are performed to diagnose acute coronary syndrome, myocardial infarction, and others. The growing prevalence of acute coronary syndrome and myocardial infarction along with growing incidences of heart failures are some prominent factors boosting demand for cardiac biomarkers globally.
Which End-use Application of Cardiac Biomarkers is Highly Popular?
“Increasing Sales of Cardiac Biomarkers for Congestive Heart Failure Diagnosis”
Myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and atherosclerosis are some prominent applications of cardiac biomarkers. Among these, biomarkers are prominently used for the diagnosis of congestive heart failure. Demand for biomarkers for congestive heart failure is forecasted to accelerate at a CAGR of 12.3% from 2023 to 2033.
Increasing cases of cardiovascular diseases, including atrial fibrillation, along with thriving demand for biomarker tests to detect heart failure at early stages is also boosting the sales of test kits across regions.
Key Market Players
Industry players are investing for numerous purposes such as ensuring quality control of products, maintaining product standards, strengthening their systems adopted for supply chain management, etc.
Key players are investing in product launches, approvals, etc., to expand their product portfolio and market reach. They are concentrating on increasing their revenue share with the development of more innovative designs of products, offering specificity of test results.
For instance :
- In April 2021, F. Hoffmann-La Roche Ltd. announced the launch of its five new applications for its prominent key cardiac biomarkers that were in combination with the company’s Elecsys technology. They work efficiently in managing cardiovascular diseases and thus assist clinicians in the diagnosis of heart attacks and managing heart failures.
- In April 2021, Siemens AG announced that the company got CE Mark approval for Atellica VTLiPatient-side Immunoassay Analyzer, which is a high-sensitivity troponin I test. This device can detect acute myocardial infarction more effectively.
Abbott, Siemens Healthineers, Randox Laboratories Ltd., Life Diagnostics, Creative Diagnostics, Quidel Corporation, F. Hoffmann-La Roche Ltd., Biomerieux SA, Bio-Rad Laboratories, and Danaher Corporation are key players in the cardiac biomarkers market.
Segmentation of Cardiac Biomarkers Industry Research
By Product :
- Creatine Kinase
- Natriuretic Peptides
- Ischemia Modified Albumin (IMA)
By Application :
- Myocardial Infarction
- Acute Coronary Syndrome (ACS)
- Congestive Heart Failure
By Location of Testing :
- Point-of-care Testing
- Laboratory Testing
By Region :
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- FAQs -
The global cardiac biomarkers market stands at US$ 13.37 billion in 2023.
Sales of cardiac biomarkers are projected to increase at a CAGR of 11% from 2023 to 2033.
Demand for troponins is increasing significantly across the globe.
Sales of cardio biomarkers for congestive heart failure are predicted to advance at a CAGR of 12.3% through 2033.
Siemens AG, Abbott, and F. Hoffmann-La Roche AG were the top 3 players in 2022 and accounted for around 30% share of the market revenue.
The market for cardiac biomarkers is estimated to reach US$ 38 billion by 2033.
Key industry players are Abbott, Siemens Healthineers, Randox Laboratories Ltd., Life Diagnostics, Quidel Corporation, F. Hoffmann-La Roche Ltd., Biomerieux SA, Bio-Rad Laboratories, and Danaher Corporation.